Celcuity to present updated Phase 3 VIKTORIA-1 gedatolisib data at ESMO 2026
CELC•Celcuity said it will present updated Phase 3 VIKTORIA-1 results on Oct. 24, 2026, with additional subgroup findings in HR+/HER2- advanced breast cancer targeting patients with PIK3CA-mutant tumors.
1. ESMO presentations
The updated VIKTORIA-1 results are scheduled for a late-breaking rapid oral session at the ESMO Congress 2026. Separate posters will compare the gedatolisib triplet in PIK3CA wild-type disease with other post-CDK4/6 regimens and report subgroup findings from a Phase 1b study of gedatolisib with darolutamide in metastatic castration-resistant prostate cancer.
